UPDATE: Protagonist Therapeutics (PTGX) Prices 7.5M Common Stock IPO at $12/Share, Flat with Expectations
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - August 11, 2016 8:58 AM EDT)
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) announced the pricing of its initial public offering of 7,500,000 shares of common stock, at a price to the public of $12 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market on August 11, 2016, under the symbol "PTGX." In addition, Protagonist has granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares at the initial public offering price, less underwriting discounts and commissions. This offering is expected to close on August 16, 2016, subject to customary closing conditions.
NOTE: The company was recently looking at a pricing range of $11 - $13 per share.
Leerink Partners LLC, Barclays Capital Inc. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 10, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus, when available, may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, copies of the preliminary prospectus relating to this offering may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at firstname.lastname@example.org, or by telephone at (800) 808-7525, ext. 4814; from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, email: Barclaysprospectus@broadridge.com; or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, telephone: (800) 414-3627, or email: email@example.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Caterpillar (CAT) Offers FY17 Guidance Update at Credit Suisse Conference
- Hoegh LNG Partners (HMLP) Announces 5.5M Common Units Offering
- WildHorse Resource Development (WRD) Launches 27.5M Common Stock IPO
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings, IPOs
Related EntitiesBMO Capital, Barclays, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!